{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:51:12Z","timestamp":1786981872616,"version":"build-2736575974"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11302-026-10156-4","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:36:59Z","timestamp":1778863019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The ATP\u2013adenosine axis as a driver of tumor-associated macrophage reprogramming in colorectal cancer: mechanistic insights into immune evasion and therapeutic vulnerabilities"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1482-4411","authenticated-orcid":false,"given":"Abdullah Faisal","family":"Albukhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"10156_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag C, Laversanne M, Vignat J, Ferlay J, Murphy N, Bray F (2022) Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72:338\u2013344. https:\/\/doi.org\/10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"key":"10156_CR2","doi-asserted-by":"publisher","unstructured":"Al-Joufi F, Setia A, Salem-Bekhit M, Sahu R, Alqahtani F, Widyowati R, & Aleanizy F (2022) Molecular pathogenesis of colorectal cancer with an emphasis on recent advances in biomarkers, as well as nanotechnology-based diagnostic and therapeutic approaches. Nanomater 12\u00a0https:\/\/doi.org\/10.3390\/nano12010169","DOI":"10.3390\/nano12010169"},{"key":"10156_CR3","doi-asserted-by":"publisher","unstructured":"Xi Y, & Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. TranslOncol 14. https:\/\/doi.org\/10.1016\/j.tranon.2021.101174","DOI":"10.1016\/j.tranon.2021.101174"},{"key":"10156_CR4","doi-asserted-by":"publisher","unstructured":"Khalaf K, Hana D, Chou J, Singh C, Mackiewicz A, & Kaczmarek M (2021) Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.656364","DOI":"10.3389\/fimmu.2021.656364"},{"key":"10156_CR5","doi-asserted-by":"publisher","unstructured":"El-Tanani M, Rabbani S, Babiker R, Rangraze I, Kapre S, Palakurthi S, Alnuqaydan A, Aljabali A, Rizzo M, El-Tanani Y, & Tambuwala M (2024) Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies.. Cancer lett 216894. https:\/\/doi.org\/10.1016\/j.canlet.2024.216894","DOI":"10.1016\/j.canlet.2024.216894"},{"key":"10156_CR6","doi-asserted-by":"publisher","unstructured":"Dzobo K, Senthebane D, & Dandara C (2023) The tumor microenvironment in tumorigenesis and therapy resistance revisited. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15020376","DOI":"10.3390\/cancers15020376"},{"key":"10156_CR7","doi-asserted-by":"publisher","unstructured":"Wang H, Tian T, & Zhang J (2021) Tumor-associated macrophages (TAMs) in colorectal cancer (CRC): from mechanism to therapy and prognosis. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms22168470","DOI":"10.3390\/ijms22168470"},{"key":"10156_CR8","doi-asserted-by":"publisher","unstructured":"Hou S, Zhao Y, Chen J, Lin Y, & Qi X (2024) Tumor-associated macrophages in colorectal cancer metastasis: molecular insights and translational perspectives. J Transl Med 22.\u00a0https:\/\/doi.org\/10.1186\/s12967-024-04856-x","DOI":"10.1186\/s12967-024-04856-x"},{"key":"10156_CR9","doi-asserted-by":"publisher","unstructured":"Gao J, Liang Y, & Wang L (2022) Shaping polarization of tumor-associated macrophages in cancer immunotherapy. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.888713","DOI":"10.3389\/fimmu.2022.888713"},{"key":"10156_CR10","doi-asserted-by":"publisher","unstructured":"Kerneur C, Cano C, & Olive D (2022) Major pathways involved in macrophage polarization in cancer. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.1026954","DOI":"10.3389\/fimmu.2022.1026954"},{"key":"10156_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004219","author":"X Zhu","year":"2022","unstructured":"Zhu X, Liang R, Lan T, Ding D, Huang S, Shao J, Zheng Z, Chen T, Huang Y, Liu J, Pathak J, Wei H, Wei B (2022) Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-004219","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10156_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111472","author":"C Dillard","year":"2021","unstructured":"Dillard C, Borde C, Mohammad A, Puchois V, Jourdren L, Larsen A, Sabbah M, Mar\u00e9chal V, Escargueil A, Pramil E (2021) Expression pattern of purinergic signaling components in colorectal cancer cells and differential cellular outcomes induced by extracellular ATP and adenosine. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms222111472","journal-title":"International Journal of Molecular Sciences"},{"key":"10156_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030808","author":"A Taruno","year":"2018","unstructured":"Taruno A (2018) ATP release channels. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms19030808","journal-title":"International Journal of Molecular Sciences"},{"key":"10156_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1124\/pharmrev.121.000528","volume":"74","author":"G Yegutkin","year":"2022","unstructured":"Yegutkin G, Boison D (2022) ATP and adenosine metabolism in cancer: exploitation for therapeutic gain. Pharmacol Rev 74:799\u2013824. https:\/\/doi.org\/10.1124\/pharmrev.121.000528","journal-title":"Pharmacol Rev"},{"key":"10156_CR15","doi-asserted-by":"publisher","unstructured":"Feng L, Cai Y, Zhu M, Xing L, & Wang X (2020) The yin and yang functions of extracellular ATP and adenosine in tumor immunity. Cancer Cell Int 20. https:\/\/doi.org\/10.1186\/s12935-020-01195-x","DOI":"10.1186\/s12935-020-01195-x"},{"key":"10156_CR16","doi-asserted-by":"publisher","unstructured":"Yang Y, Li S, To K, Zhu S, Wang F, & Fu L (2025) Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Experiment Clin Cancer Res : CR 44. https:\/\/doi.org\/10.1186\/s13046-025-03377-9","DOI":"10.1186\/s13046-025-03377-9"},{"key":"10156_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/onc.2016.206","volume":"36","author":"F Virgilio","year":"2016","unstructured":"Virgilio F, Adinolfi E (2016) Extracellular purines, purinergic receptors and tumor growth. Oncogene 36:293\u2013303. https:\/\/doi.org\/10.1038\/onc.2016.206","journal-title":"Oncogene"},{"key":"10156_CR18","doi-asserted-by":"publisher","unstructured":"Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, Qin Y, Chen Y, Cui K, Zhou L, Bian Z, Fei B, Huang S, & Huang Z (2022) Colorectal cancer\u2010derived small extracellular vesicles promote tumor immune evasion by upregulating PD\u2010L1 expression in tumor\u2010associated macrophages. Adv Sci 9. https:\/\/doi.org\/10.1002\/advs.202102620","DOI":"10.1002\/advs.202102620"},{"key":"10156_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194887","author":"G Roliano","year":"2022","unstructured":"Roliano G, Azambuja J, Brunetto V, Butterfield H, Kalil A, Braganhol E (2022) Colorectal cancer and purinergic signalling: an overview. Cancers. https:\/\/doi.org\/10.3390\/cancers14194887","journal-title":"Cancers"},{"key":"10156_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cac2.12579","volume":"44","author":"L Xiao","year":"2024","unstructured":"Xiao L, Zhang L, Guo C, Xin Q, Gu X, Jiang C, Wu J (2024) \u201cFind Me\u201d and \u201cEat Me\u201d signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer Commun 44:791\u2013832. https:\/\/doi.org\/10.1002\/cac2.12579","journal-title":"Cancer Commun"},{"key":"10156_CR21","doi-asserted-by":"publisher","unstructured":"Miyo M, Konno M, Nishida N, Sueda T, Noguchi K, Matsui H, Colvin H, Kawamoto K, Koseki J, Haraguchi N, Nishimura J, Hata T, Gotoh N, Matsuda F, Satoh T, Mizushima T, Shimizu H, Doki Y, Mori M, & Ishii H (2016) Metabolic adaptation to nutritional stress in human colorectal cancer. Sci Rep 6. https:\/\/doi.org\/10.1038\/srep38415","DOI":"10.1038\/srep38415"},{"key":"10156_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2014.12.018","volume":"160","author":"J Loo","year":"2015","unstructured":"Loo J, Scherl A, Nguyen A, Man F, Weinberg E, Zeng Z, Saltz L, Paty P, Tavazoie S (2015) Extracellular metabolic energetics can promote cancer progression. Cell 160:393\u2013406. https:\/\/doi.org\/10.1016\/j.cell.2014.12.018","journal-title":"Cell"},{"key":"10156_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112496","author":"V Vultaggio-Poma","year":"2020","unstructured":"Vultaggio-Poma V, Sarti A, Di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells. https:\/\/doi.org\/10.3390\/cells9112496","journal-title":"Cells"},{"key":"10156_CR24","doi-asserted-by":"publisher","unstructured":"Huang K, Chiang S, Lin P, Hong W, Yang P, Chang H, Peng S, Chen T, Ke T, Liang J, Chen W, & Chao K (2024) TNF\u03b1 modulates PANX1 activation to promote ATP release and enhance P2RX7-mediated antitumor immune responses after chemotherapy in colorectal cancer. Cell Death & Disease 15. https:\/\/doi.org\/10.1038\/s41419-023-06408-5","DOI":"10.1038\/s41419-023-06408-5"},{"key":"10156_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic C, Linden J (2016) Purinergic regulation of the immune system. Nat Rev Immunol 16:177\u2013192. https:\/\/doi.org\/10.1038\/nri.2016.4","journal-title":"Nat Rev Immunol"},{"key":"10156_CR26","doi-asserted-by":"publisher","unstructured":"Xia C, Yin S, To K, & Fu L (2023) CD39\/CD73\/A2AR pathway and cancer immunotherapy. Mol Cancer 22. https:\/\/doi.org\/10.1186\/s12943-023-01733-x","DOI":"10.1186\/s12943-023-01733-x"},{"key":"10156_CR27","doi-asserted-by":"publisher","unstructured":"Lin Y, Chiang S, Chen C, Hong W, Chen T, Chen W, Ke T, Yang P, Liang J, Shiau A, Chao K, & Huang K (2023) Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation. Cancer Immunol Immunother 1\u201315. https:\/\/doi.org\/10.1007\/s00262-023-03416-4","DOI":"10.1007\/s00262-023-03416-4"},{"key":"10156_CR28","doi-asserted-by":"publisher","unstructured":"G\u00f6ktuna S (2022) Characterization of differential expression patterns of the extracellular purinergic enzymes in colorectal cancer. Trakya Univ J Nat Sci. https:\/\/doi.org\/10.23902\/trkjnat.1139062","DOI":"10.23902\/trkjnat.1139062"},{"key":"10156_CR29","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2217\/fon-2023-0871","volume":"20","author":"N Kaplinsky","year":"2024","unstructured":"Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J (2024) Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol 20:1367\u20131380. https:\/\/doi.org\/10.2217\/fon-2023-0871","journal-title":"Future Oncol"},{"key":"10156_CR30","doi-asserted-by":"publisher","unstructured":"Zheng P, He J, Fu Y, Yang Y, Li S, Duan B, Yang Y, Hu Y, Yang Z, Wang M, Liu Q, Zheng X, Hua L, Li W, Li D, Ding Y, Yang X, Bai H, Long Q, Huang W & Y (2024) Engineered bacterial biomimetic vesicles reprogram tumor-associated macrophages and remodel tumor microenvironment to promote innate and adaptive antitumor immune responses.. ACS nano. https:\/\/doi.org\/10.1021\/acsnano.3c06987","DOI":"10.1021\/acsnano.3c06987"},{"key":"10156_CR31","doi-asserted-by":"publisher","unstructured":"Chen E, & Zhou W (2025) Immunotherapy in microsatellite-stable colorectal cancer: strategies to overcome resistance.. Critical rev oncol hematol 104775 . https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104775","DOI":"10.1016\/j.critrevonc.2025.104775"},{"key":"10156_CR32","doi-asserted-by":"publisher","unstructured":"Yang L, Zhang Y, & Yang L (2024) Adenosine signaling in tumor-associated macrophages and targeting adenosine signaling for cancer therapy. Cancer Biol Med 21: 995 - 1011. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2024.0228","DOI":"10.20892\/j.issn.2095-3941.2024.0228"},{"key":"10156_CR33","doi-asserted-by":"publisher","unstructured":"Augustin R, Leone R, Naing A, Fong L, Bao R, & Luke J (2022) Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2021-004089","DOI":"10.1136\/jitc-2021-004089"},{"key":"10156_CR34","doi-asserted-by":"publisher","unstructured":"Yang H, Zhang Z, Zhao K, Zhang Y, Yin X, Zhu G, Wang Z, Yan X, Li X, He T, & Wang K (2024) Targeting the adenosine signaling pathway in macrophages for cancer immunotherapy.. Human immunol 110774. https:\/\/doi.org\/10.1016\/j.humimm.2024.110774","DOI":"10.1016\/j.humimm.2024.110774"},{"key":"10156_CR35","doi-asserted-by":"publisher","unstructured":"Shi M, Ye L, Zhao L, He L, Chen J, Zhang J, Su Y, Dong H, Liu J, Liang L, Zheng W, Xiao Y, Liu H, Yang X, & Yang Z (2024) Tumor derived exosomal ENTPD2 impair CD8+ T cell function in colon cancer through ATP-adenosine metabolism reprogramming. Cell Commun Signal : CCS, 22. https:\/\/doi.org\/10.1186\/s12964-024-01654-2","DOI":"10.1186\/s12964-024-01654-2"},{"key":"10156_CR36","doi-asserted-by":"publisher","unstructured":"Wang X, Jiang S, M, Cai S, Song D, & Han B (2025) P2 purinergic receptors in tumor immunity.. Cancer res. https:\/\/doi.org\/10.1158\/0008-5472.can-24-4624.","DOI":"10.1158\/0008-5472.can-24-4624"},{"key":"10156_CR37","doi-asserted-by":"publisher","unstructured":"Jacobson K (2025) E. B. Hershberg award: taming inflammation by tuning purinergic signaling.. Acc chem res. https:\/\/doi.org\/10.1021\/acs.accounts.5c00011","DOI":"10.1021\/acs.accounts.5c00011"},{"key":"10156_CR38","doi-asserted-by":"publisher","unstructured":"Burnstock G (2018) Purine and purinergic receptors. Brain and Neurosci Adv 2. https:\/\/doi.org\/10.1177\/2398212818817494","DOI":"10.1177\/2398212818817494"},{"key":"10156_CR39","doi-asserted-by":"publisher","unstructured":"Woods L, Forti K, Shanbhag V, Camden J, & Weisman G (2021) P2Y receptors for extracellular nucleotides: contributions to cancer progression and therapeutic implications.. Biochem pharmacol 114406.\u00a0https:\/\/doi.org\/10.1016\/j.bcp.2021.114406","DOI":"10.1016\/j.bcp.2021.114406"},{"key":"10156_CR40","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.csbj.2023.01.010","volume":"21","author":"R Han","year":"2023","unstructured":"Han R, Yoon H, Yoo J, Lee Y (2023) Systematic analyses of the sequence conservation and ligand interaction patterns of purinergic P1 and P2Y receptors provide a structural basis for receptor selectivity. Comput Struct Biotechnol J 21:889\u2013898. https:\/\/doi.org\/10.1016\/j.csbj.2023.01.010","journal-title":"Comput Struct Biotechnol J"},{"key":"10156_CR41","doi-asserted-by":"publisher","unstructured":"Kanellopoulos J, Almeida-Da-Silva C, Boudinot R, & Ojcius D (2021) Structural and functional features of the P2X4 receptor: an immunological perspective. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.645834","DOI":"10.3389\/fimmu.2021.645834"},{"key":"10156_CR42","doi-asserted-by":"publisher","unstructured":"North R (2016) P2X receptors. Philosophical Transactions of the Royal Society B: Biol Sci 371. https:\/\/doi.org\/10.1098\/rstb.2015.0427","DOI":"10.1098\/rstb.2015.0427"},{"key":"10156_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coi.2018.03.026","volume":"52","author":"F Di Virgilio","year":"2018","unstructured":"Di Virgilio F, Sarti A, Grassi F (2018) Modulation of innate and adaptive immunity by P2X ion channels. Curr Opin Immunol 52:51\u201359. https:\/\/doi.org\/10.1016\/j.coi.2018.03.026","journal-title":"Curr Opin Immunol"},{"key":"10156_CR44","doi-asserted-by":"publisher","unstructured":"Santana P, De Lima I, Da Silva E Souza K, Barbosa P, & De Souza H (2024) Persistent activation of the P2X7 receptor underlies chronic inflammation and carcinogenic changes in the intestine. Int J Mol Sci 25. https:\/\/doi.org\/10.3390\/ijms252010874","DOI":"10.3390\/ijms252010874"},{"key":"10156_CR45","doi-asserted-by":"publisher","unstructured":"Xing J, Zhang J, & Wang J (2023) The immune regulatory role of adenosine in the tumor microenvironment. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms241914928","DOI":"10.3390\/ijms241914928"},{"key":"10156_CR46","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra02235e","volume":"15","author":"P Maity","year":"2025","unstructured":"Maity P, Ganguly S, Deb P (2025) Therapeutic potential of adenosine receptor modulators in cancer treatment. RSC Adv 15:20418\u201320445. https:\/\/doi.org\/10.1039\/d5ra02235e","journal-title":"RSC Adv"},{"key":"10156_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010232","author":"W Ren","year":"2021","unstructured":"Ren W, Rubini P, Tang Y, Engel T, Ill\u00e9s P (2021) Inherent P2X7 receptors regulate macrophage functions during inflammatory diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23010232","journal-title":"Int J Mol Sci"},{"key":"10156_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F, Ben D, Sarti A, Giuliani A, Falzoni S (2017) The P2X7 receptor in infection and inflammation. Immunity 47:15\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.020","journal-title":"Immunity"},{"issue":"6","key":"10156_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/wmts.62","volume":"1","author":"L Erb","year":"2012","unstructured":"Erb L, Weisman G (2012) Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdiscip Rev Membr Transp Signal 1(6):789\u2013803. https:\/\/doi.org\/10.1002\/wmts.62","journal-title":"Wiley Interdiscip Rev Membr Transp Signal"},{"key":"10156_CR50","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/bph.15005","volume":"177","author":"K Jacobson","year":"2020","unstructured":"Jacobson K, Delicado E, Gachet C, Kennedy C, K\u00fcgelgen I, Li B, Miras-Portugal M, Novak I, Sch\u00f6neberg T, P\u00e9rez-Sen R, Thor D, Wu B, Yang Z, M\u00fcller C (2020) Update of P2Y receptor pharmacology: IUPHAR review 27. Br J Pharmacol 177:2413\u20132433. https:\/\/doi.org\/10.1111\/bph.15005","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10156_CR51","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.pharmthera.2005.08.014","volume":"110","author":"I von K\u00fcgelgen","year":"2006","unstructured":"von K\u00fcgelgen I (2006Jun) Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 110(3):415\u2013432. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.08.014","journal-title":"Pharmacol Ther"},{"key":"10156_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32430-w","author":"S Coy","year":"2022","unstructured":"Coy S, Wang S, Stopka S, Lin J, Yapp C, Ritch C, Salhi L, Baker G, Rashid R, Baquer G, Regan M, Khadka P, Cole K, Hwang J, Wen P, Bandopadhayay P, Santi M, De Raedt T, Ligon K, Agar N, Sorger P, Touat M, Santagata S (2022) Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-32430-w","journal-title":"Nat Commun"},{"key":"10156_CR53","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1038\/s41388-019-0684-y","volume":"38","author":"E De Marchi","year":"2019","unstructured":"De Marchi E, Orioli E, Pegoraro A, Sangaletti S, Portararo P, Curti A, Colombo M, Di Virgilio F, Adinolfi E (2019) The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment. Oncogene 38:3636\u20133650. https:\/\/doi.org\/10.1038\/s41388-019-0684-y","journal-title":"Oncogene"},{"key":"10156_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s11302-024-10054-7","volume":"21","author":"V Manoharan","year":"2024","unstructured":"Manoharan V, Adegbayi O, Maynard J (2024) P2 purinergic receptor expression and function in tumor-related immune cells. Purinergic Signalling 21:393\u2013411. https:\/\/doi.org\/10.1007\/s11302-024-10054-7","journal-title":"Purinergic Signalling"},{"key":"10156_CR55","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.ccr-17-1283","volume":"23","author":"Y Yin","year":"2017","unstructured":"Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, Zhang J, Qin Y, Qi X, Zhou L, Fei B, Zou J, Hua D, Huang Z (2017) The immune-microenvironment confers chemoresistance of colorectal cancer through macrophage-derived IL6. Clin Cancer Res 23:7375\u20137387. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-1283","journal-title":"Clin Cancer Res"},{"key":"10156_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.7150\/thno.101001","volume":"15","author":"A Deng","year":"2025","unstructured":"Deng A, Fan R, Hai Y, Zhuang J, Zhang B, Lu X, Wang W, Luo L, Bai G, Liang L, Yang L, Zhao M, Wei G (2025) A STING agonist prodrug reprograms tumor-associated macrophage to boost colorectal cancer immunotherapy. Theranostics 15:277\u2013299. https:\/\/doi.org\/10.7150\/thno.101001","journal-title":"Theranostics"},{"issue":"4","key":"10156_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11302-023-09983-6","volume":"21","author":"WJ Zhang","year":"2025","unstructured":"Zhang WJ, Zhang LP, Lin SJ, Wang CY, Le YG (2025) P2 purinergic receptors regulate the progression of colorectal cancer. Purinergic Signal 21(4):767\u2013780. https:\/\/doi.org\/10.1007\/s11302-023-09983-6","journal-title":"Purinergic Signal"},{"key":"10156_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01356-1","author":"J Bockstiegel","year":"2023","unstructured":"Bockstiegel J, Engelhardt J, Weindl G (2023) P2X7 receptor activation leads to NLRP3-independent IL-1\u03b2 release by human macrophages. Cell Commun Signal. https:\/\/doi.org\/10.1186\/s12964-023-01356-1","journal-title":"Cell Commun Signal"},{"key":"10156_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/cells10051098","author":"D Klaver","year":"2021","unstructured":"Klaver D, Thurnher M (2021) Control of macrophage inflammation by P2Y purinergic receptors. Cells. https:\/\/doi.org\/10.3390\/cells10051098","journal-title":"Cells"},{"key":"10156_CR60","doi-asserted-by":"publisher","unstructured":"Andersen L, Huang Y, Urban C, Oubraham L, Winheim E, Stafford C, Nagl, D, O\u2019Duill F, Ebert T, Engleitner T, Paludan S, Krug A, Rad R, Hornung V, & Pichlmair A (2023) Systematic P2Y receptor survey identifies P2Y11 as modulator of immune responses and virus replication in macrophages. The EMBO J 42. https:\/\/doi.org\/10.15252\/embj.2022113279","DOI":"10.15252\/embj.2022113279"},{"key":"10156_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04548-z","author":"D Klaver","year":"2022","unstructured":"Klaver D, Gander H, Dobler G, Rahm A, Thurnher M (2022) The P2Y11 receptor of human M2 macrophages activates canonical and IL-1 receptor signaling to translate the extracellular danger signal ATP into anti-inflammatory and pro-angiogenic responses. Cell Mol Life Sci. https:\/\/doi.org\/10.1007\/s00018-022-04548-z","journal-title":"Cell Mol Life Sci"},{"key":"10156_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1074\/jbc.m006781200","volume":"276","author":"M Solle","year":"2001","unstructured":"Solle M, Labasi J, Perregaux D, Stam E, Petrushova N, Koller B, Griffiths R, Gabel C (2001) Altered cytokine production in mice lacking P2X7receptors*. J Biol Chem 276:125\u2013132. https:\/\/doi.org\/10.1074\/jbc.m006781200","journal-title":"J Biol Chem"},{"key":"10156_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837230","author":"C Sun","year":"2022","unstructured":"Sun C, Wang B, Hao S (2022) Adenosine-A2A receptor pathway in cancer immunotherapy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.837230","journal-title":"Front Immunol"},{"key":"10156_CR64","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.coph.2016.06.009","volume":"29","author":"S Hatfield","year":"2016","unstructured":"Hatfield S, Sitkovsky M (2016) A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1\u03b1 driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol 29:90\u201396. https:\/\/doi.org\/10.1016\/j.coph.2016.06.009","journal-title":"Curr Opin Pharmacol"},{"key":"10156_CR65","doi-asserted-by":"publisher","first-page":"13132","DOI":"10.1073\/pnas.0605251103","volume":"103","author":"A Ohta","year":"2006","unstructured":"Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M, Huang X, Caldwell S, Liu K, Smith P, Chen J, Jackson E, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci 103:13132\u201313137. https:\/\/doi.org\/10.1073\/pnas.0605251103","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"10156_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2016000984","volume":"1","author":"S Serra","year":"2016","unstructured":"Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen S, Arruga F, Brusa D, Coscia M, Jak\u0161i\u0107 O, Inghirami G, Rossi D, Furman R, Robson S, Gaidano G, Chiorazzi N, Deaglio S (2016) Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv 1(1):47\u201361. https:\/\/doi.org\/10.1182\/bloodadvances.2016000984","journal-title":"Blood Adv"},{"key":"10156_CR67","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0843","author":"K Schiemann","year":"2024","unstructured":"Schiemann K, Belousova N, Matevossian A, Nallaparaju K, Kradjian G, Pandya M, Chen Z, Aral E, Krauel E, Petrova E, Boesler C, Kitzing T, Lecomte M, Wagner C, Blayo A, Schann S, Huck B, Moisan J, Zaynagetdinov R (2024) Dual A2A\/ A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo. Mol Cancer Ther. https:\/\/doi.org\/10.1158\/1535-7163.mct-23-0843","journal-title":"Mol Cancer Ther"},{"key":"10156_CR68","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/jnci\/djad091","volume":"115","author":"J Evans","year":"2023","unstructured":"Evans J, Suman S, Goruganthu M, Tchekneva E, Guan S, Arasada R, Antonucci A, Piao L, Ilgisonis I, Bobko A, Driesschaert B, Uzhachenko R, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov S, Feoktistov I, Park K, Kikuchi T, Castro J, Ivanova A, Kanagasabai T, Owen D, Spakowicz D, Zweier J, Carbone D, Novitskiy S, Khramtsov V, Shanker A, Dikov M (2023) Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression. JNCI Journal of the National Cancer Institute 115:1404\u20131419. https:\/\/doi.org\/10.1093\/jnci\/djad091","journal-title":"JNCI Journal of the National Cancer Institute"},{"key":"10156_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23094585","author":"A Campos-Contreras","year":"2022","unstructured":"Campos-Contreras A, Gonz\u00e1lez-Gallardo A, D\u00edaz-Mu\u00f1oz M, V\u00e1zquez-Cuevas F (2022) Adenosine receptor A2B negatively regulates cell migration in ovarian carcinoma cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23094585","journal-title":"Int J Mol Sci"},{"key":"10156_CR70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","volume":"6","author":"R Jin","year":"2025","unstructured":"Jin R, Neufeld L, McGaha T (2025) Linking macrophage metabolism to function in the tumor microenvironment. Nature Cancer 6:239\u2013252. https:\/\/doi.org\/10.1038\/s43018-025-00909-2","journal-title":"Nature Cancer"},{"key":"10156_CR71","doi-asserted-by":"publisher","unstructured":"Qian Y, Yin Y, Zheng X, Liu Z, & Wang X (2024) Metabolic regulation of tumor-associated macrophage heterogeneity: insights into the tumor microenvironment and immunotherapeutic opportunities. Biomark Res 12. https:\/\/doi.org\/10.1186\/s40364-023-00549-7","DOI":"10.1186\/s40364-023-00549-7"},{"key":"10156_CR72","doi-asserted-by":"publisher","unstructured":"Wang S, Liu G, Li Y, & Pan Y (2022) Metabolic reprogramming induces macrophage polarization in the tumor microenvironment. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.840029","DOI":"10.3389\/fimmu.2022.840029"},{"key":"10156_CR73","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1096\/fj.11-190934","volume":"26","author":"B Cs\u00f3ka","year":"2012","unstructured":"Cs\u00f3ka B, Selmeczy Z, Koscs\u00f3 B, Nemeth Z, Pacher P, Murray P, Kepka\u2010Lenhart D, Morris S, Gause W, Leibovich S, Hasko\u0301 G (2012) Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 26:376\u2013386. https:\/\/doi.org\/10.1096\/fj.11-190934","journal-title":"FASEB J"},{"key":"10156_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e17167","author":"B Qiu","year":"2023","unstructured":"Qiu B, Yuan P, Du X, Jin H, Du J, Huang Y (2023) Hypoxia inducible factor-1\u03b1 is an important regulator of macrophage biology. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17167","journal-title":"Heliyon"},{"key":"10156_CR75","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1158\/0008-5472.can-19-2994","volume":"80","author":"P Su","year":"2020","unstructured":"Su P, Wang Q, Bi E, X, Liu L, Yang M, Qian J, & Yi Q (2020) Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res 80:1438\u20131450. https:\/\/doi.org\/10.1158\/0008-5472.can-19-2994","journal-title":"Cancer Res"},{"key":"10156_CR76","doi-asserted-by":"publisher","unstructured":"Wu H, Han Y, Sillke R, Deng H, Siddiqui S, Treese C, Schmidt F, Friedrich M, Keye J, Wan J, Qin Y, K\u00fchl A, Qin Z, Siegmund B, & Glauben R (2019) Lipid droplet\u2010dependent fatty acid metabolism controls the immune suppressive phenotype of tumor\u2010associated macrophages. EMBO Mol Med 11. https:\/\/doi.org\/10.15252\/emmm.201910698","DOI":"10.15252\/emmm.201910698"},{"key":"10156_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111281","volume":"121","author":"S Shukla","year":"2024","unstructured":"Shukla S, Dalai P, Agrawal-Rajput R (2024) Metabolic crosstalk: extracellular ATP and the tumor microenvironment in cancer progression and therapy. Cell Signal 111281. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111281","journal-title":"Cell Signal"},{"key":"10156_CR78","doi-asserted-by":"publisher","unstructured":"Wu L, Xie W, Li Y, Ni Q, Timashev P, Lyu M, Xia L, Zhang Y, Liu L, Yuan Y, Liang X, & Zhang Q (2022) Biomimetic nanocarriers guide extracellular ATP homeostasis to remodel energy metabolism for activating innate and adaptive immunity system. Adv Sci 9. https:\/\/doi.org\/10.1002\/advs.202105376","DOI":"10.1002\/advs.202105376"},{"key":"10156_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106853","volume":"87","author":"F Hajizadeh","year":"2020","unstructured":"Hajizadeh F, Masjedi A, Asl S, Kiani F, Peydaveisi M, Ghalamfarsa G, Jadidi-Niaragh F, Sevbitov A (2020) Adenosine and adenosine receptors in colorectal cancer. Int Immunopharmacol 87:106853. https:\/\/doi.org\/10.1016\/j.intimp.2020.106853","journal-title":"Int Immunopharmacol"},{"key":"10156_CR80","doi-asserted-by":"publisher","unstructured":"Xu J, Ding L, Mei J, Hu Y, Kong X, Dai S, Bu T, Xiao Q, & Ding K (2025) Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments. Signal Transduct\u00a0 Target Ther 10. https:\/\/doi.org\/10.1038\/s41392-025-02325-5","DOI":"10.1038\/s41392-025-02325-5"},{"key":"10156_CR81","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard B, Longhi M, Robson S, Stagg J (2017) The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev 276:121\u2013144. https:\/\/doi.org\/10.1111\/imr.12528","journal-title":"Immunol Rev"},{"key":"10156_CR82","doi-asserted-by":"publisher","unstructured":"Zhang L, Lu X, Xu Y, La X, Tian J, Li A, Li H, Wu C, Xi Y, Song G, Zhou Z, Bai W, An L, & Li Z (2023) Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17\/CXCL22\u2013CCR4\u2013ATF6\u2013GRP78 axis. Cell Death & Disease 14. https:\/\/doi.org\/10.1038\/s41419-023-06108-0","DOI":"10.1038\/s41419-023-06108-0"},{"key":"10156_CR83","doi-asserted-by":"publisher","unstructured":"Allard B, Allard D, Buisseret L, & Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 1\u201319. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","DOI":"10.1038\/s41571-020-0382-2"},{"key":"10156_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2022.07.020","volume":"175","author":"J Taieb","year":"2022","unstructured":"Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip J (2022) Deficient mismatch repair\/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment. Eur J Cancer 175:136\u2013157. https:\/\/doi.org\/10.1016\/j.ejca.2022.07.020","journal-title":"Eur J Cancer"},{"key":"10156_CR85","doi-asserted-by":"publisher","unstructured":"Picard E, Verschoor C, W, G, & Pawelec G (2020) Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.00369","DOI":"10.3389\/fimmu.2020.00369"},{"key":"10156_CR86","doi-asserted-by":"publisher","unstructured":"Wang J, Tang S, Fan J, Xiao H, Wang S, Xiang J, Liu Z, Liu H, Pei Z, Jiang D, Shuai L, Liu H, Ye J, Xu J, Qian C, Cui S, Xiang D, & Wu C (2025) Targeting Pin1 to overcome immunosuppressive tumor microenvironment in MSS colorectal cancer. Front Immunol 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1677029.","DOI":"10.3389\/fimmu.2025.1677029"},{"key":"10156_CR87","doi-asserted-by":"publisher","first-page":"110609","DOI":"10.1016\/j.celrep.2022.110609","volume":"39","author":"S Li","year":"2022","unstructured":"Li S, Yu J, Huber A, Kryczek I, Wang Z, Jiang L, Li X, Du W, Li G, Wei S, Vatan L, Szeliga W, Chinnaiyan A, Green M, Cieslik M, Zou W (2022) Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Rep 39:110609\u2013110609. https:\/\/doi.org\/10.1016\/j.celrep.2022.110609","journal-title":"Cell Rep"},{"key":"10156_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101175","volume":"78","author":"L Yang","year":"2024","unstructured":"Yang L, Li A, Yu W, Wang H, Zhang L, Wang D, Wang Y, Zhang R, Lei Q, Liu Z, Zhen S, Qin H, Liu Y, Yang Y, Song X, Zhang Y (2024) Blockade of purine metabolism reverses macrophage immunosuppression and enhances anti-tumor immunity in non-small cell lung cancer. Drug Resist Updat 78:101175. https:\/\/doi.org\/10.1016\/j.drup.2024.101175","journal-title":"Drug Resist Updat"},{"key":"10156_CR89","doi-asserted-by":"publisher","unstructured":"Khizar H, Ali K, & Wang J (2025) From silent partners to potential therapeutic targets: macrophages in colorectal cancer. Cancer Immunol Immunother : CII, 74. https:\/\/doi.org\/10.1007\/s00262-025-03965-w","DOI":"10.1007\/s00262-025-03965-w"},{"key":"10156_CR90","doi-asserted-by":"publisher","unstructured":"Xiang J, Wang J, Xiao H, Huang C, Wu C, Zhang L, Qian C, & Xiang D (2025) Targeting tumor-associated macrophages in colon cancer: mechanisms and therapeutic strategies. Front Immunol 16. https:\/\/doi.org\/10.3389\/fimmu.2025.1573917","DOI":"10.3389\/fimmu.2025.1573917"},{"key":"10156_CR91","doi-asserted-by":"publisher","first-page":"7378","DOI":"10.7150\/thno.113727","volume":"15","author":"H Wu","year":"2025","unstructured":"Wu H, Li J, Yao R, Liu J, Su L, You W (2025) Focusing on the interplay between tumor-associated macrophages and tumor microenvironment: from mechanism to intervention. Theranostics 15:7378\u20137408. https:\/\/doi.org\/10.7150\/thno.113727","journal-title":"Theranostics"},{"key":"10156_CR92","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer K, Smyth M (2010) Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci U S A 107:1547\u20131552. https:\/\/doi.org\/10.1073\/pnas.0908801107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10156_CR93","doi-asserted-by":"publisher","unstructured":"Kaistha B, Kar G, Dannhorn A, Watkins A, Opoku-Ansah G, Ilieva K, Mullins S, Anderton J, Galvani E, Gar\u00e7on F, Lapointe J, Brown L, Hair J, Slidel T, Luheshi N, Ryan K, Hardaker E, Dovedi S, Kumar R, Wilkinson R, Hammond S, & Eyles J (2024) Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models. Cancer Biol Ther 25\u00a0https:\/\/doi.org\/10.1080\/15384047.2023.2296048","DOI":"10.1080\/15384047.2023.2296048"},{"key":"10156_CR94","doi-asserted-by":"publisher","unstructured":"Kellner M, Von Neubeck B, Czogalla B, Feederle R, Vick B, Jeremias I, & Zeidler R (2022) A Novel Anti-CD73 Antibody that selectively inhibits membrane CD73 shows antitumor activity and induces tumor immune escape. Biomedicines 10. https:\/\/doi.org\/10.3390\/biomedicines10040825","DOI":"10.3390\/biomedicines10040825"},{"key":"10156_CR95","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","volume":"67","author":"R Leone","year":"2018","unstructured":"Leone R, Sun I, Oh M, Sun I, Wen J, Englert J, Powell J (2018) Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models. Cancer Immunol Immunother 67:1271\u20131284. https:\/\/doi.org\/10.1007\/s00262-018-2186-0","journal-title":"Cancer Immunol Immunother"},{"key":"10156_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000417","author":"A Borodovsky","year":"2020","unstructured":"Borodovsky A, Barbon C, Wang Y, Ye M, Prickett L, Chandra D, Shaw J, Deng N, Sachsenmeier K, Clarke J, Linghu B, Brown G, Brown J, Congreve M, Cheng R, Dor\u00e9 A, Hurrell E, Shao W, Woessner R, Reimer C, Drew L, Fawell S, Schuller A, Mele D (2020) Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000417","journal-title":"J Immunother Cancer"},{"key":"10156_CR97","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1038\/s41401-025-01585-9","volume":"46","author":"P Gao","year":"2025","unstructured":"Gao P, Jiang H, Du Y, Shu Y, Wan Y, Yin E, Wu J, Liang X, Wang S, Ding Z, Xu X, An Q, Miao C, He X, Li M, Liu F, Chen X (2025) CD73 inhibitor AB680 suppresses glioblastoma in mice by inhibiting purine metabolism and promoting P2RY12+ microglia transformation. Acta Pharmacol Sin 46:3053\u20133070. https:\/\/doi.org\/10.1038\/s41401-025-01585-9","journal-title":"Acta Pharmacol Sin"},{"key":"10156_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1110325","author":"X Jiang","year":"2023","unstructured":"Jiang X, Wu X, Xiao Y, Wang P, Zheng J, Wu X, Jin Z (2023) The ectonucleotidases CD39 and CD73 on T cells: the new pillar of hematological malignancy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1110325","journal-title":"Front Immunol"},{"issue":"8","key":"10156_CR99","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud H, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, D\u00e9jou C, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J, Bastid J, Romagne\u0301 F, Morel Y, Narni-Mancinelli \u00c9, Vivier \u00c9, Paturel C, Bonnefoy N (2019) Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep 27(8):2411-2425.e9. https:\/\/doi.org\/10.1016\/j.celrep.2019.04.091","journal-title":"Cell Rep"},{"key":"10156_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002503","author":"M Kim","year":"2021","unstructured":"Kim M, Min Y, Jang J, Park H, Lee S, Lee C (2021) Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-002503","journal-title":"J Immunother Cancer"},{"key":"10156_CR101","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.jcmgh.2022.07.005","volume":"14","author":"J Noh","year":"2022","unstructured":"Noh J, Lee I, Han N, Kim M, Min Y, Lee S, Yun S, Kim S, Park T, Chung H, Park D, Lee C (2022) Additive effect of CD73 inhibitor in colorectal cancer treatment with CDK4\/6 inhibitor through regulation of PD-L1. Cell Mol Gastroenterol Hepatol 14:769\u2013788. https:\/\/doi.org\/10.1016\/j.jcmgh.2022.07.005","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10156_CR102","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/2326-6066.cir-19-0833","volume":"8","author":"S Chen","year":"2020","unstructured":"Chen S, Akdemir I, Fan J, Linden J, Zhang B, Cekic C (2020) The expression of adenosine A2B receptor on antigen-presenting cells suppresses CD8+ T-cell responses and promotes tumor growth. Cancer Immunol Res 8:1064\u20131074. https:\/\/doi.org\/10.1158\/2326-6066.cir-19-0833","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"10156_CR103","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.4049\/jimmunol.163.8.4140","volume":"163","author":"J Xaus","year":"1999","unstructured":"Xaus J, Valledor A, Card\u00f3 M, Marqu\u00e9s L, Beleta J, Palacios J, Celada A (1999) Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. J Immunol 163(8):4140\u20134149. https:\/\/doi.org\/10.4049\/jimmunol.163.8.4140","journal-title":"J Immunol"},{"key":"10156_CR104","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1016\/j.apsb.2023.12.004","volume":"14","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang J, Zhang W, Zheng M, Guo H, Pan X, Li W, Yang B, Ding L (2023) The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies. Acta Pharm Sin B 14:1951\u20131964. https:\/\/doi.org\/10.1016\/j.apsb.2023.12.004","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"10156_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152362","volume":"228","author":"V Devi","year":"2023","unstructured":"Devi V, Radhika A, Biju P (2023) Adenosine receptor activation promotes macrophage class switching from LPS-induced acute inflammatory M1 to anti-inflammatory M2 phenotype. Immunobiology 228(3):152362. https:\/\/doi.org\/10.1016\/j.imbio.2023.152362","journal-title":"Immunobiology"},{"key":"10156_CR106","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.ccr-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard B, Pommey S, Smyth M, Stagg J (2013) Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 19:5626\u20135635. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-0545","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10156_CR107","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young A, Ngiow S, Barkauskas D, Sult E, Hay C, Blake S, Huang Q, Liu J, Takeda K, Teng M, Sachsenmeier K, Smyth M (2016) Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30(3):391\u2013403. https:\/\/doi.org\/10.1016\/j.ccell.2016.06.025","journal-title":"Cancer Cell"},{"key":"10156_CR108","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.cir-14-0211","volume":"3","author":"P Beavis","year":"2015","unstructured":"Beavis P, Milenkovski N, Henderson M, John L, Allard B, Loi S, Kershaw M, Stagg J, Darcy P (2015) Adenosine receptor 2A blockade increases the efficacy of anti\u2013PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 3:506\u2013517. https:\/\/doi.org\/10.1158\/2326-6066.cir-14-0211","journal-title":"Cancer Immunol Res"},{"key":"10156_CR109","doi-asserted-by":"publisher","unstructured":"Bao X, & Xie L (2022) Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death. J Experiment Clin Cancer Res : CR, 41. https:\/\/doi.org\/10.1186\/s13046-022-02430-1.","DOI":"10.1186\/s13046-022-02430-1"},{"key":"10156_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1112276","author":"J Ros","year":"2023","unstructured":"Ros J, Balconi F, Baraibar I, Gonz\u00e1lez N, Salva F, Tabernero J, \u00c9lez E (2023) Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1112276","journal-title":"Front Oncol"},{"key":"10156_CR111","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11523-019-00690-0","volume":"15","author":"R Cohen","year":"2019","unstructured":"Cohen R, Rousseau B, Vidal J, Colle R, Diaz L, Andr\u00e9 T (2019) Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond. Target Oncol 15:11\u201324. https:\/\/doi.org\/10.1007\/s11523-019-00690-0","journal-title":"Target Oncol"},{"key":"10156_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1742654","author":"Y Dai","year":"2026","unstructured":"Dai Y, Luo X, Zhang L, Yan J (2026) Roles of immunosuppressive myeloid states in colorectal cancer checkpoint inhibitor non-response: single-cell and spatial proteomics, and reprogramming approaches. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1742654","journal-title":"Front Immunol"},{"key":"10156_CR113","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan D, Young A, Teng M, Smyth M (2017) Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 17:709\u2013724. https:\/\/doi.org\/10.1038\/nrc.2017.86","journal-title":"Nat Rev Cancer"},{"key":"10156_CR114","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010126","author":"F Sun","year":"2025","unstructured":"Sun F, Yao F, Zeng C, Zhao Y, Liang B, Li S, Wang Y, Wu Q, Shi Y, Yao Z, Wang J, Jiang Y, Gu C, Huang Q, Liao W, Huang N, Wang C, Rong X, Wu J, Tan Y, Peng J, Li Y, Shi M (2025) Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-010126","journal-title":"J Immunother Cancer"},{"key":"10156_CR115","doi-asserted-by":"publisher","unstructured":"Harvey J, Phan L, Villarreal O, & Bowser J (2020) CD73\u2019s potential as an immunotherapy target in gastrointestinal cancers. Front Immunol 11. https:\/\/doi.org\/10.3389\/fimmu.2020.00508","DOI":"10.3389\/fimmu.2020.00508"},{"key":"10156_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118389","volume":"259","author":"A Giatromanolaki","year":"2020","unstructured":"Giatromanolaki A, Kouroupi M, Pouliliou S, Mitrakas A, Hasan F, Pappa A, Koukourakis M (2020) Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways. Life Sci 118389. https:\/\/doi.org\/10.1016\/j.lfs.2020.118389","journal-title":"Life Sci"},{"key":"10156_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1058371","volume":"13","author":"J Kaur","year":"2023","unstructured":"Kaur J, Dora S (2023) Purinergic signaling: diverse effects and therapeutic potential in cancer. Front Oncol 13. https:\/\/doi.org\/10.3389\/fonc.2023.1058371","journal-title":"Front Oncol"},{"key":"10156_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1006384","volume":"10","author":"M Zanoni","year":"2022","unstructured":"Zanoni M, Pegoraro A, Adinolfi E, De Marchi E (2022) Emerging roles of purinergic signaling in anti-cancer therapy resistance. Front Cell Dev Biol 10. https:\/\/doi.org\/10.3389\/fcell.2022.1006384","journal-title":"Front Cell Dev Biol"},{"key":"10156_CR119","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1158\/2767-9764.crc-25-0361","volume":"5","author":"J Powderly","year":"2025","unstructured":"Powderly J, Imbimbo M, Italiano A, Martin-Romano P, McKean M, Macarulla T, \u00c1lvarez C, Carneiro B, Mager R, Barnhart V, Eck S, Murtomaki E, Loemb\u00e9 A, He Y, Cooper Z, Tu E, Fan C, Chamard A, Paturel C, Fraenkel P, Hollebecque A (2025) IPH5201, an anti-CD39 mAb, as monotherapy or in combination with durvalumab in advanced solid tumors. Cancer Res Commun 5:1690\u20131700. https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0361","journal-title":"Cancer Res Commun"},{"key":"10156_CR120","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-19-0541","author":"X Li","year":"2019","unstructured":"Li X, Moesta A, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera A, Sundarrajan A, Jacoberger-Foissac C, Wong C, Cruz T, Welch M, Lerner A, Spatola B, Soros V, Corbin J, Anderson A, Effern M, Holzel M, Robson S, Johnston R, Waddell N, Smith C, Bald T, Geetha N, Beers C, Teng M, Smyth M (2019) Targeting CD39 in cancer reveals an extracellular ATP and inflammasome driven tumor immunity. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.cd-19-0541","journal-title":"Cancer Discov"},{"key":"10156_CR121","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00262-023-03430-6","volume":"72","author":"J Bendell","year":"2023","unstructured":"Bendell J, Lorusso P, Overman M, Noonan A, Kim D, Strickler J, Kim S, Clarke S, George T, Grimison P, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan A, Wu Y, Martin P, Cooper Z, Elgeioushi N, Mueller N, Kumar R, Patel S (2023) First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother 72:2443\u20132458. https:\/\/doi.org\/10.1007\/s00262-023-03430-6","journal-title":"Cancer Immunol Immunother"},{"key":"10156_CR122","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","volume":"131","author":"N Segal","year":"2024","unstructured":"Segal N, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley M, \u00c9lez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper Z, Kumar R, Tabernero J (2024) COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. Br J Cancer 131:1005\u20131013. https:\/\/doi.org\/10.1038\/s41416-024-02796-3","journal-title":"Br J Cancer"},{"issue":"8","key":"10156_CR123","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1208875","volume":"5","author":"C Hay","year":"2016","unstructured":"Hay C, Sult E, Huang Q, Mulgrew K, Fuhrmann S, McGlinchey K, Hammond S, Rothstein R, Rios-Doria J, Poon E, Holoweckyj N, Durham N, Leow C, Diedrich G, Damschroder M, Herbst R, Hollingsworth R, Sachsenmeier K (2016) Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 5. https:\/\/doi.org\/10.1080\/2162402x.2016.1208875","journal-title":"Oncoimmunology"},{"key":"10156_CR124","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00525","author":"K Lawson","year":"2020","unstructured":"Lawson K, Kalisiak J, Lindsey E, Newcomb E, Leleti M, Debien L, Rosen B, Miles D, Sharif E, Jeffrey J, Tan J, Chen A, Zhao S, Xu G, Fu L, Jin L, Park T, Berry W, Mosch\u00fctz S, Scaletti E, Str\u00e4ter N, Walker N, Young S, Walters M, Schindler U, Powers J (2020) Discovery of AB680 - a potent and selective inhibitor of CD73. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c00525","journal-title":"J Med Chem"},{"key":"10156_CR125","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2326-6066.cir-18-0056","volume":"6","author":"S Willingham","year":"2018","unstructured":"Willingham S, Ho P, Hotson A, Hill C, Piccione E, Hsieh J, Liu L, Buggy J, McCaffery I, Miller R (2018) A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti\u2013PD-(L)1 and anti\u2013CTLA-4 in preclinical models. Cancer Immunol Res 6:1136\u20131149. https:\/\/doi.org\/10.1158\/2326-6066.cir-18-0056","journal-title":"Cancer Immunol Res"},{"key":"10156_CR126","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.ccr-22-0612","volume":"28","author":"E Lim","year":"2022","unstructured":"Lim E, Bendell J, Falchook G, Bauer T, Drake C, Choe J, George D, Karlix J, Ulahannan S, Sachsenmeier K, Russell D, Moorthy G, Sidders B, Pilling E, Chen H, Hattersley M, Das M, Kumar R, Pouliot G, Patel M (2022) Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin Cancer Res 28:4871\u20134884. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-0612","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10156_CR127","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03640-6","volume":"73","author":"G Falchook","year":"2024","unstructured":"Falchook G, Reeves J, Gandhi S, Spigel D, Arrowsmith E, George D, Karlix J, Pouliot G, Hattersley M, Gangl E, James G, Thompson J, Russell D, Patel B, Kumar R, Lim E (2024) A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 73. https:\/\/doi.org\/10.1007\/s00262-024-03640-6","journal-title":"Cancer Immunol Immunother"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10156-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:06:46Z","timestamp":1782364006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10156-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10156"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10156-4","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study, as it is a narrative review based exclusively on previously published literature and does not involve human participants or animal experimentation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The author declares that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Language-editing tools were used to improve clarity and readability. The author retains full responsibility for the scientific content, interpretation, and integrity of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of artificial intelligence use"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"50"}}